Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

Summary

This study is a prospective,multi-center, open-label, randomized controlled clinical trial,aims to assess the clinical noninferiority of 3 months (short-term) vs 12 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in patients undergoing percutaneous coronary intervention implanted sirolimus target- eluting stent with abluminal grooves containing a biodegradable polymer (Firehawk™ stent). All participants met the inclusion criteria begin taking aspirin and open-label thienopyridine therapy before index procedure, and will be 1:1 randomized to 3 months or 12 month of DAPT at index procedure.

Timeline

Start

2019-01-10

Primary completion

2020-12

Completion

2022-10

Publications

• Yang H, Zhang F, Zhang X, Wu Y, Zhong Z, Wang J, Zhou Y, Hong L, Yang W, Jiang T, Zou J, Zhang Z, Ma Y, Wen S, Fan Z, Xu D, Jiang H, Tao J, Ren H, Xia Y, Huang Y, Xu G, Cao R, Zheng M, Qian J, Francese DP, Lansky AJ, Ge J; TARGET DAPT Investigators. Three vs 12-month DAPT after implantation of biodegradable-polymer sirolimus-eluting coronary stent: a randomised clinical trial. BMC Med. 2025 Dec 24;23(1):690. doi: 10.1186/s12916-025-04515-y.
• Yang H, Zhang F, Yang J, Zheng M, Cao R, Dai Y, Li C, Yao K, Qian J, Ge J; TARGET DAPT trial investigators. Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT trial. BMJ Open. 2019 Dec 17;9(12):e033774. doi: 10.1136/bmjopen-2019-033774.

Drugs

Indications

No indication recorded.